GlassScriptPhysician profile
Leif A Marz
NPI 1659982726
$10,672.36
in general payments reported to CMS, 2019-2025
25 companies · $790 in 2025
The $790 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $884 · 2022: $2,684 · 2023: $3,350 · 2024: $2,964 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,104.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,223.73 | 2021-2025 | Vemlidy, Biktarvy, Epclusa |
| Viiv Healthcare Company | $2,382.37 | 2022-2025 | Dovato, Apretude, Cabenuva |
| Indivior INC. | $1,284.92 | 2022-2024 | Perseris, Sublocade |
| Abbvie INC. | $1,002.17 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.36 | 2022-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Novo Nordisk INC | $356.69 | 2021-2022 | |
| Alkermes, INC. | $308.07 | 2022-2024 | Aristada, Lybalvi |
| Janssen Biotech, INC. | $299.89 | 2021-2023 | Prezcobix, Symtuza |
| Otsuka America Pharmaceutical, INC. | $248.98 | 2024-2025 | Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $229.24 | 2023-2024 | Uzedy, Austedo Xr |
| Janssen Products, LP | $212.72 | 2021-2022 | |
| Amarin Pharma, INC. | $140.38 | 2021 | |
| Merck Sharp & Dohme LLC | $135.27 | 2021-2025 | Pifeltro |
| Lilly USA, LLC | $126.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $53.00 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $51.60 | 2024 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.38 | 2023-2024 | Caplyta |
| Insulet Corporation | $33.01 | 2021 | |
| Dexcom, INC. | $32.18 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $28.37 | 2023 | Shingrix |
| Emd Serono, INC. | $24.87 | 2024 | |
| Lundbeck LLC | $20.53 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $17.78 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $16.34 | 2023 | Prehevbrio |
| Organon LLC | $15.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leif Marz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.